Compare Ishares Msci Italy ETF (EWI) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Italy ETF vs Novo Nordisk A/S — how do they compare? Ishares Msci Italy ETF trades at $60.55, while Novo Nordisk A/S trades at $51.44 (market cap $222.24B). The key difference: Novo Nordisk A/S pays a 3.56% dividend while Ishares Msci Italy ETF pays none, and Ishares Msci Italy ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| EWI | NVO | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $61.14 | $71.70 |
52-Week Low | $47.75 | $35.29 |
Market Cap | — | $222.24B |
Enterprise Value | — | $241.20B |
Dividend Yield | — | 3.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Italy ETF (EWI) trades at $60.555, showing minimal daily movement with a slight 0.12% decline. Technical indicators present a mixed picture with an overall bullish signal from moving averages but neutral oscillators, while the stock recently hit a 52-week high according to Zacks Investment Research (June 10, 2026). The fund offers exposure to Italian equities amid a complex macroeconomic environment characterized by ECB rate hikes and energy price volatility.
EWI provides targeted exposure to Italy's market recovery narrative but faces significant stagflationary risks with projected 0.5% GDP growth and inflationary pressures from Middle East conflicts. The investment case balances improving industrial data against substantial macroeconomic headwinds, creating a high-risk, potentially high-reward scenario for investors seeking European diversification.
Novo Nordisk (NVO) trades at $51.52, up 4.99% in the last session, with strong technical momentum and bullish moving averages. The company maintains robust fundamentals, including a 37.2% net income margin and consistent earnings beats in recent quarters. Recent EU approval for the Wegovy weight-loss pill (Reuters, 2026-07-15) reinforces its leadership in GLP-1 therapies, though competition is intensifying.
Outlook remains positive given solid cash flow growth and analyst support, but risks include pricing pressure from generics and slowing prescription trends. The stock's valuation at a P/E of 12.14 offers relative value in the pharma sector, with upside potential if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Italy ETF
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
